Evidence map›Paper›PMID 41846971›Full record

ArticlebioRxiv : the preprint server for biology2026

Genome-wide classification of tumor-derived reads from bulk long-read sequencing.

Toby M Baker, Nedas Matulionis, Cassidy Andrasz, Dan Gerke, Natalia Garcia-Dutton, David Atkinson, Kami Chiotti, Selina Wu, Suchita Lulla, Jieun Oh and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Toby M BakerDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0000-0002-5183-9047
Nedas MatulionisDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0000-0001-7624-3090
Cassidy AndraszDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0000-0001-5781-293X
Dan GerkeDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0009-0008-4866-6860
Natalia Garcia-DuttonDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0009-0009-6717-0534
David AtkinsonDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0009-0009-4788-4687
Kami ChiottiDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0000-0002-5466-4019
Selina WuDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0000-0001-5206-0150
Suchita LullaDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0009-0007-2301-2951
Jieun OhDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0000-0002-8961-8645
Helena WinataDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0000-0002-1001-5316
Rong-Rong HuangDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles.
Jenny LesterDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles.
Beth Y KarlanDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles.ORCID 0000-0002-9451-2933
Paul T SpellmanDivision of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles.ORCID 0000-0002-4810-0022

Funding

TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
Germline Determinants of Prostate Cancer EvolutionR01CA270108 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAUL T. SPELLMAN · 2023 to 2026
$2.9M
OHSU Center for Specialized Data Analysis as part of the GDANU24CA264007 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE, SPELLMAN, PAUL T. · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA270108NCI NIH HHS T32 CA009056NCI NIH HHS U24 CA264007
6 · The paper itself

Abstract

DNA extracted from tissue samples typically derives from a complex mixture of cell types. Without single cell analysis, it has been generally impossible to determine the cell type of origin for most molecules. One clear example of this is in the complex milieu of a human neoplasm. Here, we develop ROCIT (https://github.com/tobybaker/rocit), a transformer-based model to classify the tumor or non-tumor origin of individual reads from bulk tumor samples sequenced with long-read whole genome sequencing. Using somatic mutations to derive training data, ROCIT uses read-level methylation patterns to accurately classify reads from anywhere in the genome without requiring the adjacent normal tissue or the explicit identification of tumor differentially methylated regions. We apply ROCIT to a cohort of prostate and ovarian tumors and demonstrate high classification accuracy across the entire genome. We then demonstrate the potential of ROCIT predictions to improve somatic variant calling. ROCIT represents a major step forward in the analysis of bulk tumors with long-reads, enabling the accurate and sensitive identification of reads with specific cell types of origin genome-wide.

Identifiers

PMID41846971
PMCPMC12991090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.